Revolutionizing Monoclonal Antibody Processing
Enquyst Technologies has announced groundbreaking advancements in the purification of monoclonal antibodies (mAbs). With a focus on reducing costs and increasing efficiency, Enquyst is leading the charge with their patented Isoelectric Point Purification (IPP) technology. Traditionally, the downstream processing of mAbs has relied heavily on chromatography, which involves multiple expensive steps—namely Protein A affinity, anion exchange, and cation exchange.
Challenges with Traditional Downstream Processing
The conventional method for purifying therapeutic antibodies requires significant operational expenses and time-consuming processes. These challenges have made it vital for biotechnology firms to seek more efficient solutions. Enquyst's IPP technology diverges from these traditional approaches by offering a chromatography-free solution that demonstrates improved product yield and a reduction in impurities.
Establishing a New Standard in Purity
In a recent internal analysis, Enquyst compared its IPP technology against standard chromatography methods to purify trastuzumab biosimilars. The results were promising: not only did Enquyst's approach meet industry standards, it exceeded them by effectively eliminating Host Cell Protein (HCP) and Host Cell DNA (HC DNA) impurities. This demonstrates that the IPP technology could redefine excellence in biomanufacturing.
Dr. Jason Criscione, Founder and Chief Scientific Officer of Enquyst Technologies, emphasized the potential of the IPP technology. "These results clearly show our IPP technology's capability to revolutionize biomanufacturing by solving current challenges in downstream processing," he expressed. Excitement within the company is palpable as they continue to enhance the technology toward tackling higher goals.
A Strategic Collaboration for Future Growth
Enquyst has not only made significant strides internally but has also become a pivotal partner within the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The organization recently secured a generous funding award of $10.5 million through the Gates Grand Challenges Program, aimed at advancing efficient and cost-effective mAb manufacturing technologies. This funding will be instrumental in scaling up Enquyst's IPP technology platform, facilitating large-scale and continuous mAb production.
Preparing for Market Launch
As Enquyst prepares to introduce their revolutionary IPP systems to research use partners, plans are underway for a 2026 rollout. This timeline demonstrates Enquyst's commitment to emerging as a leader in the biotechnology landscape, providing partners and customers with cutting-edge solutions that enhance production capabilities.
About Enquyst Technologies
Enquyst Technologies is a pioneering biotechnology company dedicated to transforming the manufacturing landscape of biological drugs. The firm’s mission revolves around the development of next-generation biomanufacturing methodologies, alongside in-line analytical technologies. These innovations aim to support continuous manufacturing processes while ensuring that a wide array of transformative treatments can be provided to patients at affordable prices.
Contact Information
For more information, reach out to:
Furqan Ahmed
VP, Business Development
201-406-7215
Email: [email protected]
Frequently Asked Questions
What is IPP technology?
IPP technology is a patented purification method developed by Enquyst Technologies designed to improve the efficiency and cost-effectiveness of monoclonal antibody processing.
How does the IPP technology differ from traditional methods?
Unlike traditional chromatography methods which require multiple costly steps, IPP technology streamlines the process to reduce costs and improve product yields.
What partnerships does Enquyst have?
Enquyst collaborates with the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) as part of an initiative to advance biopharmaceutical manufacturing.
What recent funding has Enquyst received?
Enquyst has secured a $10.5 million grant via the Gates Grand Challenges Program to enhance its IPP technology platform.
When can we expect the IPP systems to launch?
The first research-use only IPP systems are planned for delivery to collaboration partners and customers starting in 2026.
